blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP2785336

EP2785336 - USE OF PEGYLATED ALCOHOLS FOR THE TREATMENT OF ACTINIC KERATOSIS [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  05.08.2016
Database last updated on 17.09.2024
Most recent event   Tooltip19.10.2018Lapse of the patent in a contracting state
New state(s): AL		published on 21.11.2018  [2018/47]
Applicant(s)For all designated states
Merz Pharma GmbH & Co. KGaA
Eckenheimer Landstrasse 100
60318 Frankfurt am Main / DE
[2014/41]
Inventor(s)01 / BARG, Heiko
Siegfriedstr. 25
69469 Weinheim / DE
02 / POOTH, Rainer
Dachbergstr. 46A
65812 Bad Soden/Taunus / DE
03 / ABTS, Harry Frank
Kurmainzer-Str. 14
61440 Oberursel / DE
04 / KIEHM, Kevin
Bettina von Arnim Strasse 8
48291 Telgte / DE
 [2014/46]
Former [2014/41]01 / BARG, Heiko
Siegfriedstr. 25
69469 Weinheim / DE
02 / POOTH, Rainer
Dachbergstr. 46A
65812 Bad Soden/Taunus / DE
03 / ABTS, Harry Frank
Kurmainzer-Str. 14
61440 Oberursel / DE
04 / KIEHM, Kevin
Landgraf-Philipp-Str. 44
60431 Frankfurt / DE
Representative(s)Michalski Hüttermann & Partner Patentanwälte mbB
Kaistraße 16A
40221 Düsseldorf / DE
[N/P]
Former [2014/41]Michalski Hüttermann & Partner Patentanwälte mbB
Speditionstraße 21
40221 Düsseldorf / DE
Application number, filing date12795340.429.11.2012
[2015/40]
WO2012EP04943
Priority number, dateEP2011019138730.11.2011         Original published format: EP 11191387
US201161564893P30.11.2011         Original published format: US 201161564893 P
[2014/41]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2013079211
Date:06.06.2013
Language:EN
[2013/23]
Type: A1 Application with search report 
No.:EP2785336
Date:08.10.2014
Language:EN
The application published by WIPO in one of the EPO official languages on 06.06.2013 takes the place of the publication of the European patent application.
[2014/41]
Type: B1 Patent specification 
No.:EP2785336
Date:30.09.2015
Language:EN
[2015/40]
Search report(s)International search report - published on:EP06.06.2013
ClassificationIPC:A61K31/08, A61P17/00, A61P17/12
[2014/41]
CPC:
A61K31/08 (EP,US); A61P17/00 (EP); A61P17/12 (EP)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2014/41]
Extension statesBANot yet paid
MENot yet paid
TitleGerman:VERWENDUNG VON PEGYLIERTEN ALKOHOLEN ZUR BEHANDLUNG VON AKTINISCHER KERATOSE[2014/41]
English:USE OF PEGYLATED ALCOHOLS FOR THE TREATMENT OF ACTINIC KERATOSIS[2014/41]
French:UTILISATION D'ALCOOLS PÉGYLÉS POUR LE TRAITEMENT DE LA KÉRATOSE ACTINIQUE[2014/41]
Entry into regional phase31.03.2014National basic fee paid 
31.03.2014Designation fee(s) paid 
31.03.2014Examination fee paid 
Examination procedure31.03.2014Examination requested  [2014/41]
25.11.2014Amendment by applicant (claims and/or description)
20.04.2015Communication of intention to grant the patent
30.04.2015Observations by third parties
12.05.2015Observations by third parties
14.08.2015Fee for grant paid
14.08.2015Fee for publishing/printing paid
14.08.2015Receipt of the translation of the claim(s)
Divisional application(s)The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is  20.04.2015
Opposition(s)01.07.2016No opposition filed within time limit [2016/36]
Fees paidRenewal fee
27.11.2014Renewal fee patent year 03
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU29.11.2012
AL30.09.2015
BE30.09.2015
BG30.09.2015
CY30.09.2015
CZ30.09.2015
EE30.09.2015
FI30.09.2015
HR30.09.2015
LT30.09.2015
LV30.09.2015
MC30.09.2015
MK30.09.2015
MT30.09.2015
PL30.09.2015
RO30.09.2015
RS30.09.2015
SI30.09.2015
SK30.09.2015
SM30.09.2015
TR30.09.2015
LU29.11.2015
NO30.12.2015
GR31.12.2015
IS30.01.2016
PT01.02.2016
[2018/47]
Former [2018/45]HU29.11.2012
BE30.09.2015
BG30.09.2015
CY30.09.2015
CZ30.09.2015
EE30.09.2015
FI30.09.2015
HR30.09.2015
LT30.09.2015
LV30.09.2015
MC30.09.2015
MK30.09.2015
MT30.09.2015
PL30.09.2015
RO30.09.2015
RS30.09.2015
SI30.09.2015
SK30.09.2015
SM30.09.2015
TR30.09.2015
LU29.11.2015
NO30.12.2015
GR31.12.2015
IS30.01.2016
PT01.02.2016
Former [2018/31]HU29.11.2012
BE30.09.2015
BG30.09.2015
CY30.09.2015
CZ30.09.2015
EE30.09.2015
FI30.09.2015
HR30.09.2015
LT30.09.2015
LV30.09.2015
MC30.09.2015
MK30.09.2015
MT30.09.2015
PL30.09.2015
RO30.09.2015
RS30.09.2015
SI30.09.2015
SK30.09.2015
SM30.09.2015
LU29.11.2015
NO30.12.2015
GR31.12.2015
IS30.01.2016
PT01.02.2016
Former [2017/41]HU29.11.2012
BE30.09.2015
BG30.09.2015
CY30.09.2015
CZ30.09.2015
EE30.09.2015
FI30.09.2015
HR30.09.2015
LT30.09.2015
LV30.09.2015
MC30.09.2015
MT30.09.2015
PL30.09.2015
RO30.09.2015
RS30.09.2015
SI30.09.2015
SK30.09.2015
SM30.09.2015
LU29.11.2015
NO30.12.2015
GR31.12.2015
IS30.01.2016
PT01.02.2016
Former [2017/39]HU29.11.2012
BE30.09.2015
BG30.09.2015
CY30.09.2015
CZ30.09.2015
EE30.09.2015
FI30.09.2015
HR30.09.2015
LT30.09.2015
LV30.09.2015
MC30.09.2015
MT30.09.2015
PL30.09.2015
RO30.09.2015
RS30.09.2015
SI30.09.2015
SK30.09.2015
SM30.09.2015
LU29.11.2015
NO30.12.2015
GR31.12.2015
IS30.01.2016
PT01.02.2016
Former [2017/03]BE30.09.2015
CZ30.09.2015
EE30.09.2015
FI30.09.2015
HR30.09.2015
LT30.09.2015
LV30.09.2015
MC30.09.2015
PL30.09.2015
RO30.09.2015
RS30.09.2015
SI30.09.2015
SK30.09.2015
LU29.11.2015
NO30.12.2015
GR31.12.2015
IS30.01.2016
PT01.02.2016
Former [2016/49]CZ30.09.2015
EE30.09.2015
FI30.09.2015
HR30.09.2015
LT30.09.2015
LV30.09.2015
MC30.09.2015
PL30.09.2015
RO30.09.2015
RS30.09.2015
SI30.09.2015
SK30.09.2015
LU29.11.2015
NO30.12.2015
GR31.12.2015
IS30.01.2016
PT01.02.2016
Former [2016/31]CZ30.09.2015
EE30.09.2015
FI30.09.2015
HR30.09.2015
LT30.09.2015
LV30.09.2015
MC30.09.2015
PL30.09.2015
RO30.09.2015
RS30.09.2015
SK30.09.2015
LU29.11.2015
NO30.12.2015
GR31.12.2015
IS30.01.2016
PT01.02.2016
Former [2016/28]CZ30.09.2015
EE30.09.2015
FI30.09.2015
HR30.09.2015
LT30.09.2015
LV30.09.2015
MC30.09.2015
PL30.09.2015
RO30.09.2015
RS30.09.2015
SK30.09.2015
NO30.12.2015
GR31.12.2015
IS30.01.2016
PT01.02.2016
Former [2016/24]CZ30.09.2015
EE30.09.2015
FI30.09.2015
HR30.09.2015
LT30.09.2015
LV30.09.2015
PL30.09.2015
RO30.09.2015
RS30.09.2015
SK30.09.2015
NO30.12.2015
GR31.12.2015
IS30.01.2016
PT01.02.2016
Former [2016/23]CZ30.09.2015
EE30.09.2015
FI30.09.2015
HR30.09.2015
LT30.09.2015
LV30.09.2015
RO30.09.2015
RS30.09.2015
SK30.09.2015
NO30.12.2015
GR31.12.2015
IS30.01.2016
Former [2016/22]CZ30.09.2015
EE30.09.2015
FI30.09.2015
HR30.09.2015
LT30.09.2015
LV30.09.2015
RS30.09.2015
NO30.12.2015
GR31.12.2015
IS30.01.2016
Former [2016/10]FI30.09.2015
HR30.09.2015
LT30.09.2015
LV30.09.2015
RS30.09.2015
NO30.12.2015
GR31.12.2015
Former [2016/09]FI30.09.2015
LT30.09.2015
LV30.09.2015
NO30.12.2015
GR31.12.2015
Former [2016/08]LT30.09.2015
NO30.12.2015
Former [2016/07]LT30.09.2015
Cited inInternational search[A]WO2010080345  (GRACEWAY PHARMACEUTICALS LLC [US], et al) [A] 1-7 * paragraphs [0001] , [0224] , [0268] *;
 [A]  - WILLIAM J MCINTYRE ET AL, "Treatment Options for Actinic Keratoses", vol. 76, no. 5, (2007), pages 667 - 671, American Family Physician, URL: http://www.aafp.org/afp/2007/0901/p667.html, (20120118), XP002667626 [A] 1-7 * the whole document *
 [A]  - RIZZO A G ET AL, "Treatment of skin neoplasms with polidocanol infiltrations. Our experience (TRATTAMENTO DELLE NEOPLASIE CUTANEE CON INFILTRAZIONI DI POLIDOCANOLO. NOSTRA ESPERIENZA)", TUMORI, IT, (20050501), vol. 4, no. 3, ISSN 0300-8916, pages S197 - S198, XP008147715 [A] 1-7 * the whole document *
other   - BUNDESINSTITUT FÜR RISIKOBEWERTUNG, "POLIDOCANOL IN KOSMETISCHEN MITTELN", STELLUNGNAHME DES BFR, (20031015), pages 1 - 5, XP003035771
    - CHEMISCHE FABRIK KREUSSLER & CO. GMBH, "POLIDOCANOL", (2012), pages 1 - 2, URL: HTTP://KREUSSLER-PHARMA.DE/ZUGANG-FUER-AERZTE-UND-APOTHEKER-FACHKREISE/PHLEBOLOGIE/2012-09-15-16-46-41/POLIDOCANOL.HTML, XP055198606
    - J. ALOS; ET AL, "EFFICACY AND SAFETY OF SCLEROTHERAPY USING POLIDOCANOL FOAM: A CONTROLLED CLINICAL TRIAL", EUROPEAN JOURNAL OF VASCULAR AND ENDOVASCULAR SURGERY, (2006), vol. 31, no. 1, pages 101 - 107, XP005198558

DOI:   http://dx.doi.org/10.1016/j.ejvs.2005.08.018
    - PARSI K; ET AL, "THE LYTIC EFFECTS OF DETERGENT SCLEROSANTS ON ERYTHROCYTES, PLATELETS,ENDOTHELIAL CELLS AND MICROPARTICLES ARE ATTENUATED BY ALBUMIN AND OTHER PLASMA COMPONENTS IN VITRO", EUROPEAN JOURNAL OF VASCULAR AND ENDOVASCULAR SURGERY, (200808), vol. 36, no. 2, pages 216 - 223, XP022831575

DOI:   http://dx.doi.org/10.1016/j.ejvs.2008.03.001
    - K ORIKASA, "STUDIES ON THE DAMAGE OF THE CULTURED ENDOTHELIAL CELLS AND K-562 CELLS BY SCLEROSANTS (ETHANOLAMINE OLEATE, AETHOXYSKLEROL AND ABSOLUTE ETHANOL) USED IN THE TREATMENT OF ESOPHAGEAL VARICES", NIHON SHOKAKIBYO GAKKAI ZASSHI, (19891001), vol. 86, no. 10, pages 2365 - 2372, XP055198633
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.